Table 2.
The main findings of pain-related tests in the study population.
| iSFN (n = 41) | sSFN (n = 44) | Sign. | |
|---|---|---|---|
| BMI (kg/m2) | 26.0 (4.3) | 27.4 (4.9) | ns. |
| Pain intensity (VAS) | 5.5 (2.3) | 6.1 (2.4) | ns. |
| DN4 | 5.0 (2.5) | 4.9 (2.0) | ns. |
| painDetect (PD-Q9) | 13.9 (7.2) | 12.1 6.0) | ns. |
| NPS | 35.0 (20.7) | 42.0 (26.6) | ns. |
| TCNS | 4.1 (2.5) | 5.1 (2.7) | ns. |
| IENFD (fibers/mm) | 3.3 (2.5) | 3.1 (3.0) | ns. |
| SENFD | 0.8 (0.6) | 0.8 (0.6) | ns. |
| ANFD | 1.3 (0.6) | 1.4 (1.0) | ns. |
Data represent the mean and (SD) of the investigated parameters. There were no significant differences between idiopathic (iSFN) and secondary SFN (sSFN) in respect of the majority of the investigated parameters. ANFD: autonomic nerve fiber density; IENFD: intraepidermal nerve fiber density; NPS: Neuropathic Pain Scale; SENFD: subepidermal nerve fiber density; TCNS: Toronto Clinical Neuropathy Scoring System; VAS: visual analogue scale; ns.: not significant difference.